Top Markets
Coin of the day
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
Peringkat dalam Saham #7142
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Harga Saham
$40.39
Terakhir disinkronkan: 2023-08-18
Kapitalisasi Pasar
$1.70B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Chinook Therapeutics, Inc. (KDNY)

Kategori

Riwayat pemecahan saham untuk Chinook Therapeutics, Inc. (KDNY)
Saham Chinook Therapeutics, Inc. (simbol: KDNY) telah mengalami total 0 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Aug 28, 2026.
Satu lembar saham KDNY yang dibeli sebelum Aug 28, 2026 sekarang setara dengan 0 lembar saham KDNY.
Daftar pemecahan saham
Tahun Pemecahan Kelipatan Kelipatan Kumulatif
Tidak cukup data untuk tanggal yang disediakan.
Pemecahan saham untuk perusahaan sejenis atau pesaing
Perusahaan Jumlah pemecahan saham Kelipatan Kumulatif Negara
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH